Published in Blood on January 20, 2010
Dlk1 is necessary for proper skeletal muscle development and regeneration. PLoS One (2010) 1.28
Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One (2012) 1.11
Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors. Oncogene (2011) 0.91
DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo. Cancer Lett (2011) 0.91
The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies. Front Genet (2011) 0.88
Long non-coding RNAs in haematological malignancies. Int J Mol Sci (2013) 0.83
The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas. Int J Oncol (2013) 0.82
Long noncoding RNAs during normal and malignant hematopoiesis. Int J Hematol (2014) 0.82
Long non-coding RNAs in normal and malignant hematopoiesis. Oncotarget (2016) 0.81
Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma. Clin Epigenetics (2014) 0.80
Associations Between Fetal Imprinted Genes and Maternal Blood Pressure in Pregnancy. Hypertension (2016) 0.78
Effect of DLK1 on tumorigenesis in CD34(+)CD38(-) bone marrow cells in myelodysplastic syndromes. Oncol Lett (2013) 0.77
Unique patterns of evolutionary conservation of imprinted genes. Clin Epigenetics (2011) 0.77
Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis. Leukemia (2015) 0.76
Interaction of delta-like 1 homolog (Drosophila) with prohibitins and its impact on tumor cell clonogenicity. Mol Cancer Res (2013) 0.75
TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population. Oncotarget (2017) 0.75
An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol (2017) 0.75
Prognostic values of DLK1 for surgery and imatinib mesylate adjuvant therapy in gastrointestinal stromal tumors. Am J Cancer Res (2016) 0.75
Targeting endogenous DLK1 exerts antitumor effect on hepatocellular carcinoma through initiating cell differentiation. Oncotarget (2016) 0.75
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2002) 3.97
Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer (2007) 3.10
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03
Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell (2011) 2.68
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res (2004) 1.73
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res (2010) 1.73
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma (2007) 1.70
Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med (2008) 1.41
Symptom burden and supportive care in patients with acute leukemia. Leuk Res (2013) 1.37
Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One (2010) 1.36
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2003) 1.26
Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer (2009) 1.25
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood (2005) 1.24
Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med (2012) 1.24
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol (2009) 1.22
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther (2008) 1.21
Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene (2004) 1.15
Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene (2002) 1.15
Focus group study of hand hygiene practice among healthcare workers in a teaching hospital in Toronto, Canada. Infect Control Hosp Epidemiol (2010) 1.11
Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol (2006) 1.09
Cancer patient perceptions on the ethical and legal issues related to biobanking. BMC Med Genomics (2013) 1.08
Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS One (2010) 1.08
Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest (2012) 1.04
Traumatic stress in acute leukemia. Psychooncology (2011) 1.04
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther (2010) 1.03
The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol (2007) 1.02
Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. Mol Cell Biol (2004) 1.00
Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol (2003) 1.00
A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood (2011) 0.99
Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res (2004) 0.97
Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol (2008) 0.94
A novel ENU-generated truncation mutation lacking the spectrin-binding and C-terminal regulatory domains of Ank1 models severe hemolytic hereditary spherocytosis. Exp Hematol (2010) 0.94
Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. Crit Rev Oncol Hematol (2008) 0.94
Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol (2008) 0.93
Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Mol Cancer Res (2008) 0.91
Direct genetic analysis of ten cancer cells: tuning sensor structure and molecular probe design for efficient mRNA capture. Angew Chem Int Ed Engl (2011) 0.90
Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res (2003) 0.89
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood (2013) 0.89
Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. Leuk Res (2003) 0.88
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. Am J Hematol (2011) 0.88
Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res (2005) 0.87
Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. Chem Biol (2011) 0.87
Preleukemia: the normal side of cancer. Curr Opin Hematol (2015) 0.86
The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood (2010) 0.85
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. Br J Haematol (2012) 0.85
Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leuk Res (2012) 0.85
Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Leuk Res (2012) 0.84
Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer (2012) 0.84
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. Br J Haematol (2014) 0.84
The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells. Breast Cancer Res (2007) 0.84
Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy. Leuk Lymphoma (2004) 0.83
Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom (2006) 0.83
NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases. Biochem Biophys Res Commun (2003) 0.83
Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer (2008) 0.82
Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patients. Leuk Lymphoma (2007) 0.81
Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. Leuk Lymphoma (2010) 0.80
A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. Clin Lymphoma Myeloma Leuk (2012) 0.80
Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. PLoS One (2013) 0.80
A pilot phase II RCT of a home-based exercise intervention for survivors of AML. Support Care Cancer (2013) 0.79
Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression. Biochim Biophys Acta (2012) 0.79
Lyl1 interacts with CREB1 and alters expression of CREB1 target genes. Biochim Biophys Acta (2007) 0.79
Genetic determinants of mouse hepatitis virus strain 1 pneumovirulence. J Virol (2010) 0.78
Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol (2013) 0.78
Occupational medicine practice: one specialty or three? J Occup Environ Med (2010) 0.78
Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling. Proc Natl Acad Sci U S A (2013) 0.78
Respirator physiologic impact in persons with mild respiratory disease. J Occup Environ Med (2010) 0.78
Cytopenia induction by 5-fluorouracil identifies thrombopoietic mutants in sensitized ENU mutagenesis screens. Exp Hematol (2011) 0.78
Respirator physiological effects under simulated work conditions. J Occup Environ Hyg (2009) 0.77
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leuk Res (2013) 0.77
Occupational medicine practice: activities and skills of a national sample. J Occup Environ Med (2010) 0.77
Multidomain subjective response to respirator use during simulated work. J Occup Environ Med (2009) 0.77
FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients. Leuk Res (2012) 0.76
Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis (2015) 0.76
Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis (2015) 0.76
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele. PLoS One (2013) 0.76
Health care crisis in Gaza. CMAJ (2009) 0.75
Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells. Apoptosis (2015) 0.75
Subjective response to respirator type: effect of disease status and gender. J Occup Environ Med (2010) 0.75
Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies. Br J Haematol (2003) 0.75
Malignant mimicry. Am J Med (2010) 0.75
Career paths in occupational medicine. J Occup Environ Med (2012) 0.75
Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation. Br J Haematol (2014) 0.75
Prevalence of gastrointestinal problems in occupations: a retrospective study. J Occup Environ Med (2011) 0.75
Value of occupational medicine board certification. J Occup Environ Med (2013) 0.75
A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. Br J Haematol (2014) 0.75